Investigational drug · Phase 2
RS-113
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RS-113"
First trial start
2024
Oct 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RS-113", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RS-113" as an intervention, largest first.
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerPivotal-lookingActive, not recruiting
R-Pharm International, LLCIndustry
NCT07553988 · 120 participants (planned) · Start Oct 24, 2024 · Primary completion May 14, 2026
Drug: RS-113, 160 mg; RS-113, 240 mg and 4 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Arkhangelsk, Russia; Istra, Russia; Ivanovo, Russia · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model.
Song J, Kim J, Lee MJ, et al. · Parkinsonism Relat Disord 2022
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus R, Sestak I, Kronenwett R, et al. · J Natl Cancer Inst 2016
- Validation of EBUS-TBNA-integrated nodal staging in potentially node-positive non-small cell lung cancer.
Sakairi Y, Hoshino H, Fujiwara T, et al. · Gen Thorac Cardiovasc Surg 2013
- Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor RS-113,456.
Karwowski JK, Markezich A, Whitson J, et al. · J Surg Res 1999
- Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model.
Abbruzzese TA, Guzman RJ, Martin RL, et al. · Surgery 1998
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.